-155 targets myosin light chain kinase and modulates actin cytoskeleton organization in endothelial cells. Am J Physiol Heart Circ Physiol 306: H1192-H1203, 2014. First published January 31, 2014; doi:10.1152/ajpheart.00521.2013.-Previously, we identified a microRNA (miRNA) signature for endothelial cells (ECs) subjected to unidirectional shear stress (USS). MiR-155, a multifunctional miRNA that has been implicated in atherosclerosis, was among the shear stress-responsive miRNAs. Here, we examined the role of miR-155 in modulating EC phenotype and function. In vitro, increased miR-155 levels in human ECs induced changes in morphology and filamentous (F)-actin organization. In addition, ECs transfected with miR-155 mimic were less migratory and less proliferative and had less apoptosis compared with control ECs. In mouse aorta, miR-155 expression was increased in the intima of thoracic aorta, where blood flow produces steady and unidirectional shear stress, compared with the intima of the lower curvature of the aortic arch, which is associated with oscillatory and low shear stress. These differences in miR-155 expression were associated with distinct changes in EC morphology and F-actin. The effects of miR-155 in vitro were mediated through suppression of two key regulators of the EC cytoskeleton organization: RhoA and myosin light chain kinase (MYLK). A novel direct interaction between miR-155 and the MYLK 3=UTR was verified by luciferase-MYLK 3=UTR reporter assays. Furthermore, the intensity of immunofluorescence staining for RhoA and MYLK in mouse aorta correlated inversely with miR-155 expression. In conclusion, a prominent effect of the multifunctional miR-155 in ECs is modulation of phenotype through alterations in RhoA, MYLK expression, and actin cytoskeleton organization. microRNA; shear stress; endothelial cell; cytoskeleton; stress fibers MICRORNAS (miRNAs) are a class of short, single-stranded, noncoding RNAs that are important posttranscriptional regulators of genes involved in an array of cellular functions, including differentiation, growth, proliferation, and apoptosis (1, 11, 14) . Endothelial cells (ECs), which line the luminal surface of the blood vessel wall and constitutively express specific miRNAs (12, 24) , are the primary sensors of mechanical forces associated with blood flow and circulating signaling molecules (5, 23). Different biochemical and mechanical stimuli can induce dramatic changes in EC gene expression that, in turn, lead to changes in EC morphology, migration, growth, proliferation, apoptosis, and production of vasoactive substances (4). Recent work by our group (32) and others (18, 19, 31) has indicated that modulation of EC gene expression in response to biochemical and mechanical stimuli is mediated by specific miRNAs, ultimately leading to changes in EC phenotype and function. Because ECs are crucial to modulating many aspects of vascular homeostasis, miRNA-mediated changes in EC phenotype and function are likely important determinants of vascular health and the development of vascular disease, such as atherosclerosis (8, 29).
type and function. Because ECs are crucial to modulating many aspects of vascular homeostasis, miRNA-mediated changes in EC phenotype and function are likely important determinants of vascular health and the development of vascular disease, such as atherosclerosis (8, 29) .
MiR-155 was one of the miRNAs that was regulated in ECs by shear stress forces (32) . MiR-155 is the product of the B-cell integration cluster gene (7) and is regarded as a multifunctional miRNA. MiR-155 is expressed in multiple cell types, and it has been implicated in regulating several biological processes, including hematopoiesis, inflammation, and immunity (7) . Interestingly, the small GTPase RhoA has been shown to be directly targeted for suppression by miR-155 (10) .
RhoA and myosin light chain kinase (MYLK) are important regulators of EC actin cytoskeleton organization (2, 28) . RhoA activates several downstream proteins, including Rho-associated kinase (ROCK), LIM kinase, and cofilin, which contribute to stress fiber formation and cell adhesion. Stress fibers are actomyosin bundles of filamentous actin (F-actin) linked to phosphorylated myosin light chain (p-MLC). MYLK phosphorylates myosin light chain (MLC) at Serine 19 and Threonine 18, leading to a conformational change in the myosin structure that promotes stress fiber formation (16) . MYLK mediates cell contraction, which contributes to cell junction opening and EC monolayer hyperpermeability in response to inflammatory agents (30) . Both RhoA and MYLK signaling have been implicated in cell migration and proliferation. Importantly, MYLK was recently shown to have an important role in atherosclerotic plaque formation. In fact, atherosclerotic mice deficient in the MYLK gene have reduced plaque formation and enhanced EC monolayer barrier function (25) .
In this study, we tested the hypothesis that miRNA-155 (miR-155) modulates EC phenotype through changes in actin cytoskeleton organization. This hypothesis was based on our observations of miR-155 expression and changes in actin cytoskeleton organization in different segments of mouse aorta. We found that increased levels of miR-155 in human ECs attenuated EC migration, proliferation, and apoptosis, and it induced distinct changes in EC morphology. Our data indicate that miR-155-induced changes in EC cytoskeleton organization are mediated through suppression of RhoA and MYLK, the latter mRNA being a novel target for miR-155. Although recent studies have indicated that miRNA-induced changes in EC gene expression are likely reflective of the action of multiple miRNAs, the current study focused on the expression of a single miRNA. In doing so, this work provides valuable insight into the molecular mechanisms by which miRNA expression can fine tune EC gene expression and phenotype in vitro and in vivo.
METHODS

Cell cultures. Human umbilical vein endothelial cells (HUVECs;
Genlantis), passages 2-6, were cultured in medium 199 containing 20% FBS, 40 g/ml endothelial mitogen, 13.3 U/ml heparin, antibiotics, and 1% L-glutamine. HEK293 cells were cultured in DMEM with 10% FBS, antibiotics, and 1% L-glutamine.
Animals. This study included 12-wk-old male C57BL/6 mice (Jackson Laboratories). All animal studies were approved by the Atlanta Veterans Administration Medical Center Institutional Animal Care and Use Committee in accordance with the guidelines set forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
In vitro shear stress model. HUVECs were seeded on 0.4 mm -slides (Ibidi) 24 h before the experiment. The slide was connected to an air pressure pump using the 15-cm ID1.6 mm perfusion set; 8 ml of culture media was pumped with a pressure of 23.1 mbar (USS) or 7.2 mbar (OSS) and a flow rate of 5.69 ml/min (USS) and 1.89 ml/min (OSS), generating shear stress of ϩ14.98 dynes/cm 2 (USS) and Ϯ 4.98 dynes/cm 2 OSS. Harvesting ECs from mouse aorta. The removal of the intimal layer from mouse aorta was performed as described previously (9) . Briefly, 12-wk-old male C57BL/6 mice were euthanized and pressure perfused (0.9% saline solution), and their aortas were dissected into two areas: the lower curvature of the aortic arch and the thoracic aorta. Dissected tissues were stained with Accustain nuclear stain (Sigma) and then treated with liberase enzyme (Roche), making it possible to gently scrape off the intimal layer of the vessel using a 25-gauge needle. MiRNA was isolated using the miRVana kit (Ambion).
miR-155 mimic transfection. HUVECs were split 24 h before transfection. Transient transfection was performed using siPort NeoFX transfection reagent (AB; Ambion) according to the manufacturer's protocol. Also, 10 nM miR-155 mimic (Ambion) and 10 nM control (negative control mimic; Ambion) were used, cells were incubated for 24 h, and media was changed and cells were harvested at 24 h later.
miR-155 inhibition. In most experiments, HUVECs were transiently transfected as described above with 100 nM miR-155 inhibitor (Ambion) or 100 nM control (negative control inhibitor; Ambion). For the proliferation assay, we used a lentivirus construct containing either anti-miR-155 sequence or a control sequence (miRZIP155 or miR-ZIP000, respectively, SBI). HEK293 cells were transfected with 2 g lentivirus construct using lipofectamine 2000 and Plus Reagent (Invitrogen) according to the manufacturer's protocol. Optimal Plasmid expression was followed by monitoring green fluorescent protein fluorescence. MiRZIP000 or miRZIP155 transfected cell medium containing the lentivirus particles was collected and used to transduce HUVECs. Fourty-eight hours after transduction, ECs were cultured in the presence of selective antibiotic Puromycin (1.5 g/ml; Sigma).
Small interfering RNA transfection. For knockdown of RhoA and MYLK proteins, HUVECs were transiently transfected as described above with 200 nM small interfering (si)RhoA (Santa Cruz) or/and 100 nM siMYLK (Santa Cruz, pool of 3 siRNA) for 24 h. Media was changed, and cells were harvested or fixed 24 h later.
microRNA quantitative RT-PCR. Quantitative assessment of specific miRNA levels was measured using standard protocols from Applied Biosystems and Qiagen. Cycle threshold (Ct) values of the analyzed miRNAs were normalized to Ct values obtained for the noncoding, small nuclear RNA molecule U6. Data were expressed as fold change versus control.
Western analysis. Western analysis was performed as previously described (21) . Antibodies against MYLK (1:5,000) and ␤-actin (1:5,000) were obtained from Abcam, and ROCK-2 (1:500) and RhoA (1:1,000) antibodies were from Santa Cruz. As loading control, anti-GAPDH (1:1,000; Santa Cruz) antibody was used.
Rho activity. The activity of RhoA in relation to total RhoA protein was determined using an ELISA kit from Cytoskeleton. Experiments were performed according to manufacturer's instructions.
ROCK activity. Rho-activated kinase (ROCK) activity was estimated using the ELISA-based ROCK Assay from Cell Biolabs, following the manufacturer's protocol.
Immunofluorescence. HUVECs were cultured on a glass cover slip and transfected as described above. Forty-eight hours after transfection, cells were fixed with 4% paraformaldehyde solution, permeablized with 0.1% Triton X, and quenched using 50 mM ammonium chloride in PBS. Primary antibodies (RhoA, MYLK, AT 1R, Abcam) were used as 1:100 dilutions in 3% BSA and incubated overnight at 4°C; secondary antibody dilution was 1:50 in 3% BSA for 1 h at room temperature (Rhodamine-Red-X anit-rabbit or anti-mouse; Jackson Immuno Research). F-actin was stained (1:100, Alexa 488 Phalloidin; Invitrogen) for 1 h at RT, and DAPI (Sigma) was used as a nuclear stain at 1:1,000 dilution for 15 min at RT. Cells were then mounted on glass slides and pictures were taken with Olympus Fluoview confocal microscope. Quantitative analysis was performed using the Fluoview software. Single cells were outlined, and the integrated fluorescence intensity was divided by the area of each cell.
MYLK 3=UTR construct design. The complete MYLK 3=UTR was cloned into the pMir-Target vector (WT). The pMir-Target vector was obtained from OriGene. Three mutant constructs (MT-1, MT-2, MT-3) were created using primer overlap extension PCR. For MT-1: 5=-CCTAGCAGCGTTATTGATGGGacTgAATCTATGTTAGT-TGGCACC-3=, sense and antisense: 5=-GGTGCCAACTAACATAGATTcAgtCCATCAATAACGCTGCTAGG-3=, and for MT-2: 5=-ACTTGTCATGAGTGTAAagATaAAGGACATTATGCTTCTTC-GATTC-3= and 5=-GAATCGAAGAAGCATAATGTCCTTtATctTTA-CACTCATGACAAGT-3=. Both sets of primers were used for MT-3. MT-1 had changes in three nucleotides at position 178 -184 of the MYLK 3=UTR. MT-2 had 3 nucleotides mutated in the MYLK 3=UTR at position 587-593. MT-3 had both putative miR-155 binding sites mutated. All constructs were sequenced.
Luciferase activity. HEK293 cells were transfected with 2 g of plasmid DNA, which included empty vector (EV), wild type MYLK 3=UTR (WT), or mutant MYLK 3=UTR constructs MT-1-3, using Lipofectamine 2000 and Plus Reagent (Invitrogen). Cells were treated with G418 and passaged until most cells expressed the plasmid, detected by red fluorescence protein. Cells were then transfected with 10 nM miR-155 mimic or control miRNA. Forty-eight hours after transfection, cells were lysed and luciferase activity was measured using Brightlite (Promega) and a Victor Luminometer according to the manufacturer's protocol.
Cell proliferation. HUVECs were transfected with miR-155 mimic or miR-155 inhibitor and the appropriate miRNA control for 48 h and then incubated with 10 m BrdU for 24 h. In vitro BrdU kit (BD PharMingen) was used as described by the manufacturer. Briefly, the cells were fixed with ethanol-containing fixation buffer and washed with Perm/Wash buffer. For BrdU staining, cells were labeled by FITC-conjugated anti-BrdU antibody for 20 min at room temperature. After incubation, cells were washed and resuspended with FACS staining buffer. Finally, BrdU-treated HUVECs were analyzed using a FACSCalibur Flow Cytometry (BD Biosciences). The percentage of green fluorescent-positive cells was calculated using the CellQuest software.
Scratch wound healing assay. HUVECs were transfected with miR-155 mimic (10 nM) or inhibitor (100 nM), as described above, and grown on 6-well dishes until confluency (ϳ48 h after transfection). A straight line/wound was scratched into the HUVEC monolayer using a 100 l pipet tip. The area was photographed and marked, and then the cells were placed back in the incubator. After 12 h, the same area was photographed again, and the cells that had migrated into the wound area were counted.
Caspase-3 activity. For assessment of caspase-3 activity, transfected HUVECs were treated with 10 ng/l LPS in 0.5% FBS medium for 24 h. Caspase-3 activity was measured with the ApoAlert Caspase 3 Colorimetric Assay Kit (Clontech) according to the manufacturer's instructions.
Statistics. All data were reported as means Ϯ SE. Comparisons between two groups were performed using t-test and among multiple groups by ANOVA. A value of P Ͻ 0.05 was considered to be statistically significant.
RESULTS
MiR-155 is regulated by shear stress in vitro and in vivo.
Previously, we found miR-155 to be increased in HUVECs subjected to 24 h of USS compared with static (no shear) conditions (32) . Figure 1A shows a comparison of miR-155 expression in HUVECs exposed to no shear, oscillatory shear stress (OSS; Ϯ 5 dynes/cm 2 ), or unidirectional shear stress (USS; ϩ15 dynes/cm 2 ) for 24 h. We found a significant increase in miR-155 expression in ECs subjected to USS, compared with cells subjected to static or OSS conditions. The increase in miR-155 levels was observed as early as 1 h of USS (Fig. 1B) . Interestingly, the expression of pre-miR-155 and the miR-155 host gene (B-cell integration cluster gene) did not change in response to 24 h of shear stress ( Fig. 1 , C and D), suggesting that USS-induced changes in expression of mature miR-155 were not due to increased transcription. In addition, there were no shear-induced changes in expression of the passenger strand of the pre-miR-155 duplex, miR-155* (Fig. 2E) .
With the use of a method to isolate the intimal layer from mouse aorta, the expression of miR-155 was assessed in the lower curvature of the aortic arch, where shear stress forces are low and oscillatory (27) , and the descending thoracic aorta, where shear stress forces are steady and unidirectional. Intimal layer preparations from the thoracic aorta had increased miR-155 expression compared with those from the lower curvature of the aortic arch ( Fig. 2A) . Similar to what was observed in cultured ECs, the intimal layer preparations did not show any difference in pre-miR-155 expression (Fig. 2B) . In addition, the mRNA levels of smooth muscle cell ␣-actin and von Willebrand Factor (vWF) did not differ between the two segments (Fig. 2, C and D) , indicating that the intimal preparations were similar in regard to their EC and non-EC content. We observed similar aortic segment-associated changes in expression for miR-126, an EC-specific miRNA that is also regulated by shear stress forces (32) (not shown). Together, these data indicate that miR-155 expression is regulated in human ECs in vitro and mouse aorta in vivo, suggesting a role MiR-155 expression and changes in EC function. In gainand loss-of-function studies, levels of miR-155 were increased in HUVECs via transfection of a miR-155 mimic, whereas miR-155 expression was suppressed by using a miR-155 inhibitor. Subsequently, EC migration and proliferation were assessed. Using a scratch/wound migration assay, we found that increased miR-155 levels were associated with attenuated EC migration into the wound area compared with control cells (Fig. 3, A and B) . Inhibition of miR-155 did not affect EC migration. ECs transfected with the miR-155 mimic had less BrdU staining (assessed by FACS), indicating a decrease in cell proliferation (Fig. 3C) . In contrast, we found that miR-155 inhibition increased cell proliferation compared with control. In addition, ECs transfected with the miR-155 mimic had decreased caspase-3 activity, indicating decreased apoptosis (Fig. 3D ). Overall these data show that changes in miR-155 expression influenced important features of EC function that involve actin cytoskeleton organization, including migration and proliferation.
MiR-155 expression and changes in EC actin cytoskeleton organization. In en face preparations of mouse aorta, the morphology of ECs in segments associated with high miR-155 expression (i.e., thoracic aorta) was elongated and aligned with the direction of flow (Fig. 4A, right) . In contrast, ECs in aortic segments associated with low miR-155 expression (i.e., lower curvature of aortic arch; Fig. 4A , left) had contracted cell morphology with a distinct cobblestone shape, prominent cortical actin rim, and no uniform orientation. The two aortic segments, which had distinct differences in miR-155 expression, also demonstrated differences in F-actin staining (green): the endothelial layer of the lower curvature of the aortic arch had increased F-actin compared with the endothelial layer of the thoracic aorta (Fig. 4, A and B) .
In vitro, we observed a striking visible change in cell morphology of ECs with increased miR-155 levels compared with those transfected with the control mimic (Fig. 4C ). HUVECs treated with the miR-155 mimic were elongated, whereas control cells had the characteristic cobblestone appearance of HUVECs grown under static conditions. F-actin staining (green; Fig. 4D ) revealed that actin stress fibers were less dense in ECs treated with miR-155 mimic compared with control cells, which showed a more contracted cell shape. No difference in cell morphology or F-actin staining was observed in cells treated with a miR-155 inhibitor (Fig. 4, D and E) . ECs treated with miR-155 mimic had 65% less F-actin (Fig. 4E) , and the stress fibers were aligned with the long axis of the cell. Importantly, there was no difference in ␤-actin protein expression in HUVECs overexpressing miR-155 (not shown), suggesting that changes in F-actin were not associated with alteration of total actin content of the cells. Together, our findings indicate that miR-155 expression modulated the EC cytoskeleton organization primarily by decreasing stress fibers in vivo and in vitro.
MiR-155 suppressed RhoA protein expression. We examined the impact of miR-155 expression on signaling pathways that regulate EC actin cytoskeleton organization. Expression of the small GTPase RhoA has been shown to be suppressed by miR-155 in NMuMG epithelial cells (10) . Immunofluorescence intensity of en face preparations from mouse aortic segments showed that RhoA protein was significantly lower in ECs of the thoracic aorta compared with those in the lower curvature (Fig. 5, A and B) , suggesting an association between miR-155 expression and RhoA in vivo. However, we did not find a significant difference in RhoA mRNA levels in intima preparations of the aortic arch compared with the thoracic aorta (Fig. 5C ). Subsequently, we assessed whether RhoA expression was inhibited by miR-155 in cultured human ECs. ECs transfected with the miR-155 mimic had a 75% decrease in RhoA protein levels, whereas inhibition of miR-155 increased RhoA protein levels compared with controls (Fig. 5D) . Furthermore, we found that protein expression of ROCK-2, which is downstream of RhoA, was also decreased by miR-155 mimic, whereas inhibition of miR-155 increased ROCK-2 protein expression (not shown). Interestingly, we found that the ratio of active RhoA to total RhoA was increased in cells transfected with the miR-155 mimic (Fig.   5E ). In addition, we did not detect any change in the ratio of ROCK activity to total protein in cells overexpressing miR-155 (not shown). These findings suggest that there may be a compensatory mechanism whereby activation of RhoA is enhanced while the levels of total RhoA are decreased in Fig. 3 . miR-155 expression alters endothelial cell (EC) function. A: representative images of EC scratch/wound assay; cells were transfected with either miR-155 mimic (10 nM) or miR-155 inhibitor (100 nM) and appropriate controls. Lines mark the scratched wound area. B: quantification of cells migrated into the scratched area. Transfection of miR-155 mimic decreased EC migration (*P ϭ 0.011; n ϭ 6), whereas inhibition of miR-155 did not significantly alter EC migration (ns ϭ not significant). C: EC proliferation (BrdU incorporation; FACS) was decreased in cells transfected with miR-155 mimic (10 nM) and increased in cells treated with miR-155 inhibitor (100 nM). *P ϭ 0.0002, n ϭ 8, and **P ϭ 0.027, n ϭ 8, respectively. D: apoptosis (caspase-3 activity) in HUVECs transfected with 10 nM miR-155 mimic; data indicate fold change over control. miR-155 mimic (10 nM) significantly decreased EC apoptosis (*P ϭ 0.0004, n ϭ 6).
cells that have elevated miR-155 levels. These data indicated that posttranscriptional inhibition of RhoA by miR-155 modulated the RhoA signaling pathway, thereby leading to alteration of EC actin cytoskeleton organization and cell morphology.
MiR-155 suppressed MYLK expression. In addition to RhoA, MYLK is another important regulator of the cell cytoskeleton organization. MYLK phosphorylates MLC, which in turn promotes stress fiber formation (16) . Immunofluorescence intensity of en face preparations from aortic segments showed that MYLK protein was significantly lower in the intima of the thoracic aorta compared with those in the lower curvature (Fig. 6, A and B) , suggesting an association between expression of miR-155 and MYLK in ECs in vivo. However, we did not detect any differences in MYLK mRNA in the intimal layer preparations from mouse aorta. An in silico analysis (www.targetscan.org) revealed that there are two possible binding sites for miR-155 in the MYLK 3=UTR. These binding sites include one highly conserved sequence at position 178 -184 of the MYLK 3=UTR and one poorly conserved sequence at position 587-593. Increased levels of miR-155 in HUVECs de- creased both MYLK mRNA and protein (Fig. 6C) , suggesting that MYLK mRNA was targeted by miR-155 in ECs. In contrast, inhibition of miR-155 did not significantly alter MYLK mRNA or protein expression (Fig. 6C) .
A direct interaction between miR-155 and the human MYLK 3=UTR was verified using luciferase reporter assays (Fig. 6D) . HEK293 cells were transfected with miR-155 mimic and luciferase reporter constructs containing either the full length, wild-type MYLK 3=UTR (WT) or mutant versions of the MYLK 3=UTR (MT-1, MT-2, MT-3). MT1 had a mutation in the highly conserved miR-155 binding site, MT-2 had a mutation in the poorly conserved miR-155 binding site, and MT-3 had mutations in both miR-155 binding sites. Figure 6D shows that miR-155 inhibited luciferase activity in cells containing either WT vector or MT-2 vector compared with those treated with empty vector (EV). In contrast, miR-155 had no significant effect on luciferase activity in cells containing MT-1 vector or MT-3 vector. Together these findings indicate The intensity of immunofluorescence staining for both RhoA and MYLK protein in mouse aorta appeared to inversely correlate with the expression of miR-155 (Figs. 5A and 6A) , suggesting that miR-155 modulates the RhoA and MYLK pathways in vivo. In addition, we assessed whether differences in miR-155 expression in different segments of mouse aorta inversely correlated with another known target, angiotensin receptor type 1 (AT 1 R) (15) . Indeed, the intensity of immunofluorescence staining for AT 1 R in the intimal layer of the thoracic aorta was suppressed relative to staining for AT 1 R in intimal layer of the lower curvature of the aortic arch (Fig. 6,  E and F) .
The effect of RhoA and MYLK knockdown on EC cytoskeleton. We used siRNA against RhoA and MYLK to examine the effect of knocking down one or both of these targets on EC morphology and cytoskeleton organization. Although siRhoA dramatically decreased RhoA protein expression in . Treatment with miR-155 mimic decreased activity of WT (*P ϭ 0.009; n ϭ 6) and MT-2 (**P ϭ 0.043; n ϭ 6). RFP, red fluorescence protein. E: angiotensin II type 1 receptor (AT1R) expression was increased in the lower curvature of mouse aorta compared with thoracic aorta. For representative confocal images of en face preparations, AT1R immunofluorescence is red and nuclei are blue (DAPI). F: quantitative analysis of AT1R fluorescence intensity/area (*P ϭ 0.011; n ϭ 3).
HUVECs compared with control siRNA-treated cells (Fig. 7A) , EC morphology and stress fiber staining in cells treated with siRhoA (Fig. 7B) were not markedly different than control siRNA-treated cells. Knockdown of MYLK with siRNA to levels comparable with that seen with miR-155 mimic (Fig.  7C ) induced morphologic changes in the cells, but the intensity of F-actin fluorescence was not different between siMYLK and control-transfected cells (Fig. 7D) . Interestingly, knockdown of both RhoA and MYLK simultaneously induced changes in EC morphology similar to that observed after transfection with miR-155 mimic (Fig. 7E) . These ECs had decreased F-actin and less intense stress fibers, and the EC morphology was more elongated compared with control cells. These observations suggest that miR-155-induced changes in EC morphology and cytoskeleton organization were due to suppression of both RhoA and MYLK.
DISCUSSION
The early atherosclerotic plaque is characterized by EC activation and dysfunction, including increased apoptosis, proliferation, migration, monocyte adhesion, and enhanced permeability of the EC monolayer to inflammatory macromolecules and leukocytes (8, 29) . MiR-155 is a multifunctional miRNA that has been implicated as having a role in atherosclerosis and has been shown to be expressed in differentiating lymphoid and myeloid cells, monocytes, macrophages, B cells, T cells, dendritic cells, fibroblasts, vascular smooth muscle cells, and endothelial cells. In our previous miRNA profile of HUVECs exposed to 24 h of USS, miR-155 was among the 13 microRNAs that were significantly increased and thus shear stress responsive (32) . Here, the changes in EC phenotype and function induced by miR-155 were examined. We found that miR-155 expression was increased by USS relative to OSS, both in vitro and in vivo. Transfection of ECs with a miR-155 mimic induced an atheroprotective phenotype, characterized by cells that were less migratory, less proliferative, and less apoptotic. We also found that miR-155 induced a dramatic change in EC morphology, which was associated with attenuated expression of RhoA and MYLK. Suppression of these genes through transfection of miR-155 mimic or siRNA altered F-actin and stress fiber formation. Furthermore, we observed a similar relationship between expression of miR-155, RhoA, and MYLK in vivo, in the lower curvature of the aortic arch and the thoracic aorta. Together, these findings provide novel insight into how miRNA expression, specifically miR-155, modulates EC phenotype and function.
Interestingly, two recent reports have described both proand anti-atherogenic roles for miR-155 in macrophages (17, 33) . In both cases, miR-155 expression was increased in atherosclerotic tissues and cultured cells treated with oxidized LDL, but its role in plaque progression differed, depending on its mRNA target. Nazari-Jahantigh and colleagues (17, 33) demonstrated that suppression of BCL6 by miR-155 led to enhanced expression of CCL2, a chemokine that promotes the recruitment of monocytes to atherosclerotic plaque. They showed that leukocyte-specific deficiency of miR-155 reduced plaque size and the number of macrophages in lesions of atherosclerotic mice (ApoE Ϫ/Ϫ ). In contrast, Zhu and colleagues (33) showed that miR-155 could decrease levels of the inflammatory cytokines IL-6 and TNF-␣ in oxidized LDLtreated macrophages and in a mouse model of atherosclerosis. In this latter study, plaque staining for macrophages and plaque progression was dramatically reduced in atherosclerotic mice injected with miR-155 mimic. This anti-atherogenic effect of miR-155 was felt to be mediated through inhibition of MAP3K10.
In the current study, we found that increased miR-155 levels were linked to atheroprotective changes in EC phenotype. A similar atheroprotective effect of miR-155 in ECs has been reported by Zhu and coworkers (34) . Indeed, increased miR-155 levels attenuated ANG II-mediated upregulation of the inflammatory genes VCAM1, MCP1, and FLT. MiR-155 also reduced ANG II-induced EC migration and adhesion of Jurkat T cells to EC. These investigators showed that the antiinflammatory effects of miR-155 were mediated through its targeting of the transcription factor Ets-1 and AT 1 R, a known target of miR-155 (15) .
Interestingly, it was recently reported that miR-155 mediated the proinflammatory effect of TNF-␣ on ECs (26) . TNF-␣ treatment increased miR-155 expression in HUVECs, which directly decreased the stability of eNOS mRNA. Furthermore, statin treatment, which is known to increase eNOS expression in ECs (13) , was shown to negatively regulate miR-155 expression, both under basal conditions and in response to TNF-␣, and this effect appeared to be mediated through RhoA/ ROCK inhibition. Our findings, together with the other studies, indicate that miR-155-mediated regulation of gene expression and EC phenotype is complex. It is likely that the atheroprotective or atherogenic functions of miR-155 are dependent on the stimulus, miRNA levels, and experimental conditions. For example, we have found divergent effects of miR-155 on EC apoptosis that were dependent on the concentration of miR-155 mimic transfected into the cells. Apoptosis, assessed by caspase-3 activity, was decreased when HUVECs were transfected with 10 nM of miR-155 mimic (Fig. 3D) , whereas apoptosis was increased when 100 nM of miR-155 mimic was transfected (not shown). Because USS increases eNOS expression (22) , enhanced miR-155 expression may induce changes in actin cytoskeleton organization, as shown here, while also functioning to modulate eNOS expression and activity (22) . This may be important for cell survival because excessive production of nitric oxide is cytotoxic.
In the current study, we used the 10 nM concentration of miR-155 mimic because it was associated with increased cell survival, which is characteristic of the EC atheroprotective phenotype. Unfortunately, due to differences in methods used to enhance miR-155 levels (miRNA mimic vs. adenovirus), it is not possible to compare intracellular miR-155 levels between our study and previous studies (26) .
We observed very little to no effect of miR-155 inhibition on EC function and phenotype. This lack of effect is not surprising, particularly because miR-155 expression in ECs is very low at baseline; further lowering of miR-155 levels in cells with low baseline expression would be expected to have minimal effects on EC function and phenotype. Inhibition of miR-155 in cells subjected to USS was technically challenging. We observed only a 50% reduction in miR-155 in nonsheared ECs (not shown). When we transfected the miR-155 inhibitor into ECs subjected to USS, we did not observe any differences in miR-155 expression compared with control cells. This may be reflective of the method used to inhibit miR-155, or it could indicate that the shear stress stimulus is able to overcome exogenous miR-155 inhibitor.
The endothelial cytoskeletal contractile machinery plays an important role in cell migration, proliferation, and barrier properties of the endothelium. The importance of RhoA and MYLK pathways in EC actin cytoskeleton organization has been described previously (2, 3, 6, 17) . RhoA is a known target of miR-155, which was validated in the current study. Inhibition of MYLK expression in ECs has been shown to decrease p-MLC, thereby preventing stress fiber formation, cell contraction, and intracellular gaps (2, 6) . There is also emerging evidence that MYLK is involved in cellular responses that are independent of MLC phosphorylation, including cell migration (25) . Importantly, MYLK has a role in atherosclerotic plaque formation; atherosclerotic mice deficient in the MYLK gene have reduced plaque formation and enhanced EC monolayer barrier function (25) . Our study is the first to show that MYLK is also a direct target of miR-155.
Our findings suggest a role for miR-155 in regulation of RhoA and MYLK in ECs. The effects of siRhoA and siMYLK in ECs indicate that miR-155-mediated changes in actin cytoskeleton organization require suppression of both genes. This finding is not unexpected given that an important feature of miRNAs is their ability to target multiple mRNAs and thereby potentially modulate different signaling pathways involved in the same cellular process.
Shear stress-induced changes in miR-155 levels indicate that expression of this miRNA is responsive to physiologic stimuli. However, in vitro and in vivo, USS and OSS are powerful stimuli that regulate the expression of dozens of genes in a time-and dose-dependent manner. Our strategy of overexpressing one miRNA is not expected to completely recapitulate the dynamic changes in actin cytoskeleton organization that occur over time in response to shear stress forces (17) . Indeed, we failed to detect a difference in RhoA and MYLK protein levels between ECs that had been subjected to USS or OSS for 24 h. These findings support the role of miR-155 as a fine-tuner of EC gene expression rather than a master regulator.
It is likely that the 24-h time point failed to capture temporal changes in RhoA and MYLK induced by shear stress in vitro. However, the changes in theses genes observed after transfection of cultured ECs with miR-155 mimic were similar to those observed in mouse thoracic aorta, where miR-155 expression is relatively high compared with other segments of aorta. Specifically, we found that mouse thoracic aorta had similar changes in cell morphology, F-actin staining, and RhoA and MYLK expression. Our findings are important because they directly link miR-155 expression with different pathways involved in altering EC phenotype in response to physiologic stimuli. miRNAs are considered to be fine-tuners of gene expression, cell phenotype, and cell function, and the miRNA-mediated changes in EC phenotype and function that occur in response to various physiologic stimuli most certainly involve the action of multiple miRNAs (20, 31) . Studies such as the current one, which examine the impact of one miRNA on EC gene expression and function, are very important for identifying specific targets and the effects of their suppression on distinct signaling pathways. However, future studies will need to examine the impact on EC function of changes in expression of multiple miRNAs.
